Home > Research . Search . Country . Browse . Small Grants

PSC In The News

RSS Feed icon

Singh discusses her research in India on infertility

Johnston concerned declines in teen smoking threatened by e-cigarettes

Frey discusses book Diversity Explosion

Highlights

Apply for 2-year NICHD Postdoctoral Fellowships that begin September 2015

PSC Fall 2014 Newsletter now available

Martha Bailey and Nicolas Duquette win Cole Prize for article on War on Poverty

Michigan's graduate sociology program tied for 4th with Stanford in USN&WR rankings

Next Brown Bag

Monday, Jan 12
Filiz Garip, Changing Dynamics of Mexico-U.S. Migration

Edward Norton photo

Improving Cost-Benefit Analysis of Tobacco Regulation

a PSC Research Project

Investigators:   Edward Norton, Jeffrey A. Smith, Helen Levy

In November 2010, the Food and Drug Administration (FDA), in its first significant attempt to regulate tobacco in more than a decade, proposed regulations requiring graphic warning labels on cigarette packages. Like all major rules, this one was accompanied by a legally required regulatory impact analysis enumerating the rule?s costs and benefits. This regulation was, not surprisingly, met with immediate opposition from the tobacco industry, including pointed criticism about the method that FDA used to value the lost consumer surplus associated with reductions in smoking ? that is, smokers? foregone enjoyment. In the analysis accompanying the final rule issued in August 2011, the FDA used a compromise method to value lost consumer surplus and estimated that it would offset between 76 and 93 percent of health benefits to smokers associated with the regulation.
This regulation has not yet taken effect because of an ongoing legal challenge. Whether or not this particular rule withstands judicial scrutiny, any future attempt to regulate tobacco at the Federal level will have to provide evidence that health benefits outweigh costs?including the foregone enjoyment of smoking. Given the size of the FDA?s estimate of the foregone enjoyment relative to the health benefits of the smoking regulation, an accurate method for valuing lost consumer surplus is essential to the effective regulation of tobacco. The methods currently used by FDA do not have a sound theoretical or empirical foundation, and this issue is simply too important not to get right. Therefore, we propose to address the question: how should the FDA estimate the value of smokers? lost consumer surplus?that is, foregone enjoyment?associated with regulation-induced changes in smoking?

Funding Period: 09/12/2013 to 08/31/2015

Search . Browse